Botulinum neurotoxin type A subtype 2 confers greater safety than subtype 1 in a rat Parkinson's disease model.

Itakura, Masanori; Kohda, Tomoko; Kubo, Takeya; Semi, Yuko; Nishiyama, Kazuhiro; Azuma, Yasu-Taka; Nakajima, Hidemitsu; Kozaki, Shunji; Takeuchi, Tadayoshi

Itakura, Masanori; Kohda, Tomoko; Kubo, Takeya; Semi, Yuko; Nishiyama, Kazuhiro; Azuma, Yasu-Taka; Nakajima, Hidemitsu; Kozaki, Shunji; Takeuchi, Tadayoshi.

Affiliation

Itakura M; Laboratory of Veterinary Pharmacology, Graduate School of Life and Environmental Science, Osaka Prefecture University, 1-58 Rinku Ourai Kita, Izumisano-shi, Osaka 598-8531, Japan.

J Vet Med Sci ; 76(8): 1189-93, 2014 Aug.

Article in En | MEDLINE | ID: mdl-24849052

Subject(s)

Botulinum Toxins, Type A/adverse effects; Botulinum Toxins, Type A/pharmacology; Corpus Striatum/drug effects; Parkinson Disease/drug therapy; Synaptosomal-Associated Protein 25/metabolism; Animals; Blotting, Western; Botulinum Toxins, Type A/administration & dosage; Dopaminergic Neurons/drug effects; Fluorescent Antibody Technique; Proteolysis; Rats; Weight Loss/drug effects

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parkinson Disease / Botulinum Toxins, Type A / Corpus Striatum / Synaptosomal-Associated Protein 25 Limits: Animals Language: En Journal: J Vet Med Sci Journal subject: MEDICINA VETERINARIA Year: 2014 Type: Article Affiliation country: Japan

Fulltext

XML

PubMed Links

Search on Google